TORONTO, ONTARIO--(Marketwire - November 05, 2009) - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for the operating room, announced today that it is expanding the scope of its Q3-2009 financial results conference call, scheduled for November 12, 2009 at 10 AM ET, to include a live webcast presentation. During the webcast, Dr. Arun Menawat, Novadaq President and CEO, will present an update on recent clinical and economic results from studies involving the SPY Imaging System. The webcast will also include a short discussion on the potential for future strategic partnerships. Those planning to participate in the webcast should reserve approximately 45 minutes.
To access the live webcast: Please login 5-10 minutes prior to event start time. Go to website: http://www.investorcalendar.com/IC/CEPage.asp?ID=151467 Select "3rd Qtr. 2009 Financial Results", fill in login information, and then click 'OK' A pop-up window will open to display the web conference To access the live conference call: Live Participant Dial-In (Toll Free): (877) 407-0778 Live Participant Dial-In (International): (201) 689-8565 Technical Support and Vcall System Requirements: For technical assistance while logging on, or during the conference, you may dial star 0 if you are listening by telephone. If not listening by telephone, or if you require technical support prior to the conference, you may write to support@vcall.com or call: (North America):+1.866.490.5412 (International) + 1.302.824.7749. To review Vcall Interactive System Requirements please visit http://www.vcall.com/vcall/support/systemrequirements.aspxA telephonic replay of the conference call will be made available until midnight on 12/12/09 and can be accessed by dialing 1-877-660-6853 (within Canada and the United States) or 1-201-612-7415 (international callers) and entering the account number 286 and the conference identification number 336494 when prompted. The webcast will be archived for 365 days on the company's website at http://www.novadaq.com under the "Events" tab in the Investors section. In addition, a replay of the call will be available for download to a portable audio player or computer, as an MP3 or podcast file, at the same location on Novadaq's website.
About Novadaq Technologies Inc.
Novadaq develops and commercializes real-time imaging systems for use in the operating room. Novadaq's SPY® Imaging System uniquely enables surgeons to visualize blood vessels, blood flow in tissue, tumors, tumor margins and the lymphatic system in real-time during surgery. This core technology is now being applied across multiple surgical markets such as cardiac, plastic and reconstructive, gastrointestinal, urological, general, micro and transplant. The PINPOINT™ System for endoscopic autofluorescence imaging is Novadaq's first minimally invasive product.
PINPOINT allows surgeons to differentiate between healthy and cancerous tissue in the lung and other hollow organs. Expanding its portfolio of minimally invasive products, Novadaq offers SPY scope, which combines the typical features of a standard endoscope with the capabilities of SPY Imaging. The ability to visualize tissue perfusion and flow through vessels, ducts and the lymphatic system adds another dimension to the images available to surgeons during endoscopic surgical procedures. Novadaq also leverages its core technology to offer the OPTTX® System, which is designed for the diagnosis, evaluation and treatment of wet Age-related Macular Degeneration (AMD). Novadaq is the exclusive United States distributor of PLC Medical's CO2 HEART LASER™ System, which is used in the same cardiac procedures as the SPY Imaging System. For more information, please visit the company's website at http://www.novadaq.com.
Forward-Looking Statements
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, results of future clinical tests of PINPOINT, SPY scope and the SPY Imaging System, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Business strategies, especially those involving arrangements with third parties, are subject to various risks and uncertainties and there can be no assurance that any such arrangements, whether joint venture, partnership or otherwise, will occur, or if they occur, as to the terms thereof. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
